Format

Send to

Choose Destination
Curr Opin Hematol. 2013 Mar;20(2):130-6. doi: 10.1097/MOH.0b013e32835dd862.

Hematopoietic stem cell transplantation for myelofibrosis: where are we now?

Author information

1
Division of Hematology and Medical Oncology, Center for Hematologic Malignancies, OHSU Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon 97239, USA. fleischm@ohsu.edu

Abstract

PURPOSE OF REVIEW:

A succinct yet comprehensive review of the biology of myeloproliferative neoplasms and therapeutic options with a focus on rational decision making for hematopoietic stem cell transplantation.

RECENT FINDINGS:

The introduction of Janus kinase inhibitors for myelofibrosis have ushered in a new era for treatment of constitutional symptoms and splenomegaly in myelofibrosis, but the effect of these agents on the natural history of the disease has yet to be clearly defined. Reduced intensity transplants have emerged as the preferred option with recent evidence suggesting fludarabine and melphalan as the optimal conditioning regimen.

SUMMARY:

Myelofibrosis is a rare hematologic malignancy with limited curative therapeutic options. Significant advances in our understanding of disease pathogenesis have led to new targets and new therapeutic options are forthcoming. Hematopoietic stem cell transplantation is at present the only treatment with curative intent; however, the selection of patients who are likely to be best served by this procedure is difficult. As myelofibrosis is an extremely rare disease, randomized clinical trials specifically investigating the role of transplantation in myelofibrosis are unlikely to occur, thus current decision making processes are best guided by retrospective analyses from registry databases and single institution experiences.

PMID:
23314844
DOI:
10.1097/MOH.0b013e32835dd862
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center